Databases
Indications
Compound classes
#trials/ # subjects
RA
Rheumatoid arthritis (RA)
Psoriatic arthritis (PsA) or psoriasis (Ps)
All biologics
Newer synthetic DMARDS
Older drugs as active control
94/ 38,460
Neuropathic Pain
Diabetic neuropathy (DPN)
Post herpetic neuralgia (PHN)
Fibromyalgia
All drugs approved or in development
Older drugs as active control
57*/ 17,390*
Osteoporosis
Prevention and treatment of post
menopausal osteoporosis
Bisphosphonates, HRT, SERMs, calcitonin,
PTH
Newer therapies
78*/ 108,000*
HCV
Chronic HCV
Long-acting pegylated interferons
Newer small molecules
Older drugs as active control
128/ 35,728
Depression
Major depression
All approved treatments
All registration trials (minimize impact of
publication bias)
75/17,667
Schizophrenia
Schizophrenia monotherapy, and
add-on therapy for refractory
Schizophrenia
Typical & atypical anti-psychotics
Augmentation treatments
114/26203
Alzheimer's
Alzheimer's
Geriatric Cognitive Impairment
NMDA Antagonists
AChE Inhibitors
Abeta Drugs & others in development
155/TBD
Dyslipidemia
Dyslipidemia, progression of
atherosclerosis, prevention of CV
events
Statins, fibrates, cholesterol absorption
inhibitors, Niacin
Over 500/TBD
Notice: The information contained in this electronic mail message is intended
only for the use of the designated recipient. This message is privileged and
confidential. and the property of GVK BIO or its affiliates and subsidiaries.
If the reader of this message is not the intended recipient or an agent
responsible for delivering it to the intended recipient, you are hereby
notified that you have received this message in error and that any review,
dissemination, distribution, or copying of this message is strictly prohibited.
If you have received this communication in error, please notify us immediately
by telephone +91-40-66929999 and destroy any and all copies of this message in
your possession (whether hard copies or electronically stored copies).